Literature DB >> 16021525

Perlecan displays variable spatial and temporal immunolocalisation patterns in the articular and growth plate cartilages of the ovine stifle joint.

James Melrose1, Susan Smith, Martin Cake, Richard Read, John Whitelock.   

Abstract

Perlecan is a modular heparan sulphate and/or chondroitin sulphate substituted proteoglycan of basement membrane, vascular tissues and cartilage. Perlecan acts as a low affinity co-receptor for fibroblast growth factors 1, 2, 7, 9, binds connective tissue growth factor and co-ordinates chondrogenesis, endochondral ossification and vascular remodelling during skeletal development; however, relatively little is known of its distribution in these tissues during ageing and development. The aim of the present study was to immunolocalise perlecan in the articular and epiphyseal growth plate cartilages of stifle joints in 2-day to 8-year-old pedigree merino sheep. Perlecan was prominent pericellularly in the stifle joint cartilages at all age points and also present in the inter-territorial matrix of the newborn to 19-month-old cartilage specimens. Aggrecan was part pericellular, but predominantly an extracellular proteoglycan. Perlecan was a prominent component of the long bone growth plates and displayed a pericellular as well as a strong ECM distribution pattern; this may indicate a so far unrecognised role for perlecan in the mineralisation of hypertrophic cartilage. A significant age dependant decline in cell number and perlecan levels was evident in the hyaline and growth plate cartilages. The prominent pericellular distribution of perlecan observed indicates potential roles in cell-matrix communication in cartilage, consistent with growth factor signalling, cellular proliferation and tissue development.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16021525     DOI: 10.1007/s00418-005-0789-y

Source DB:  PubMed          Journal:  Histochem Cell Biol        ISSN: 0948-6143            Impact factor:   4.304


  61 in total

Review 1.  Heparan sulfate proteoglycans: intricate molecules with intriguing functions.

Authors:  R V Iozzo
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

Review 2.  FGFs, heparan sulfate and FGFRs: complex interactions essential for development.

Authors:  D M Ornitz
Journal:  Bioessays       Date:  2000-02       Impact factor: 4.345

Review 3.  The molecules of mechanosensation.

Authors:  J Garcia-Anoveros; D P Corey
Journal:  Annu Rev Neurosci       Date:  1997       Impact factor: 12.449

4.  Characterization of recombinant perlecan domain I and its substitution by glycosaminoglycans and oligosaccharides.

Authors:  M Costell; K Mann; Y Yamada; R Timpl
Journal:  Eur J Biochem       Date:  1997-01-15

5.  Electrophoretic, biosensor, and bioactivity analyses of perlecans of different cellular origins.

Authors:  S Knox; J Melrose; J Whitelock
Journal:  Proteomics       Date:  2001-12       Impact factor: 3.984

6.  The C-terminal domain V of perlecan promotes beta1 integrin-mediated cell adhesion, binds heparin, nidogen and fibulin-2 and can be modified by glycosaminoglycans.

Authors:  J C Brown; T Sasaki; W Göhring; Y Yamada; R Timpl
Journal:  Eur J Biochem       Date:  1997-11-15

7.  The mechanism of aggrecan release from cartilage differs with tissue origin and the agent used to stimulate catabolism.

Authors:  Robert Sztrolovics; Robert J White; Peter J Roughley; John S Mort
Journal:  Biochem J       Date:  2002-03-01       Impact factor: 3.857

8.  Perlecan protein core interacts with extracellular matrix protein 1 (ECM1), a glycoprotein involved in bone formation and angiogenesis.

Authors:  Maurizio Mongiat; Jian Fu; Rachel Oldershaw; Robert Greenhalgh; Allen M Gown; Renato V Iozzo
Journal:  J Biol Chem       Date:  2003-02-25       Impact factor: 5.157

9.  Formation of heparan sulfate or chondroitin/dermatan sulfate on recombinant domain I of mouse perlecan expressed in Chinese hamster ovary cells.

Authors:  R Kokenyesi; J E Silbert
Journal:  Biochem Biophys Res Commun       Date:  1995-06-06       Impact factor: 3.575

10.  Perlecan maintains the integrity of cartilage and some basement membranes.

Authors:  M Costell; E Gustafsson; A Aszódi; M Mörgelin; W Bloch; E Hunziker; K Addicks; R Timpl; R Fässler
Journal:  J Cell Biol       Date:  1999-11-29       Impact factor: 10.539

View more
  18 in total

Review 1.  Recent progress in histochemistry and cell biology: the state of the art 2005.

Authors:  Douglas J Taatjes; Jürgen Roth
Journal:  Histochem Cell Biol       Date:  2005-11-11       Impact factor: 4.304

2.  Comparative spatial and temporal localisation of perlecan, aggrecan and type I, II and IV collagen in the ovine meniscus: an ageing study.

Authors:  James Melrose; Susan Smith; Martin Cake; Richard Read; John Whitelock
Journal:  Histochem Cell Biol       Date:  2005-10-28       Impact factor: 4.304

Review 3.  The histochemistry and cell biology vade mecum: a review of 2005-2006.

Authors:  Douglas J Taatjes; Christian Zuber; Jürgen Roth
Journal:  Histochem Cell Biol       Date:  2006-11-24       Impact factor: 4.304

4.  Epiphyseal abnormalities, trabecular bone loss and articular chondrocyte hypertrophy develop in the long bones of postnatal Ext1-deficient mice.

Authors:  Federica Sgariglia; Maria Elena Candela; Julianne Huegel; Olena Jacenko; Eiki Koyama; Yu Yamaguchi; Maurizio Pacifici; Motomi Enomoto-Iwamoto
Journal:  Bone       Date:  2013-08-17       Impact factor: 4.398

5.  Proteoglycans in Normal and Healing Skin.

Authors:  Margaret Mary Smith; James Melrose
Journal:  Adv Wound Care (New Rochelle)       Date:  2015-03-01       Impact factor: 4.730

6.  Topographical variation in the distributions of versican, aggrecan and perlecan in the foetal human spine reflects their diverse functional roles in spinal development.

Authors:  Susan M Smith; John M Whitelock; Renato V Iozzo; Christopher B Little; James Melrose
Journal:  Histochem Cell Biol       Date:  2009-08-11       Impact factor: 4.304

7.  Colocalization in vivo and association in vitro of perlecan and elastin.

Authors:  Anthony J Hayes; Megan S Lord; Susan M Smith; Margaret M Smith; John M Whitelock; Anthony S Weiss; James Melrose
Journal:  Histochem Cell Biol       Date:  2011-08-28       Impact factor: 4.304

8.  Knockdown of the pericellular matrix molecule perlecan lowers in situ cell and matrix stiffness in developing cartilage.

Authors:  Xin Xu; Zhiyu Li; Yue Leng; Corey P Neu; Sarah Calve
Journal:  Dev Biol       Date:  2016-08-27       Impact factor: 3.582

9.  Tissue-engineered cartilaginous constructs for the treatment of caprine cartilage defects, including distribution of laminin and type IV collagen.

Authors:  Lily Jeng; Hu-Ping Hsu; Myron Spector
Journal:  Tissue Eng Part A       Date:  2013-06-19       Impact factor: 3.845

10.  Aggrecan, versican and type VI collagen are components of annular translamellar crossbridges in the intervertebral disc.

Authors:  James Melrose; Susan M Smith; Richard C Appleyard; Christopher B Little
Journal:  Eur Spine J       Date:  2007-10-31       Impact factor: 3.134

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.